Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 221 publications
Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes.
Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes.
Journal: JCO precision oncology
Published: August 26, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 20, 2026
Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 07, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Journal: JAMA oncology
Published: June 25, 2026
HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.
Journal: ESMO open
Published: April 11, 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 28, 2026
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer.
Journal: Breast cancer research and treatment
Published: November 23, 2025
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in BRCA1.
Journal: Current oncology (Toronto, Ont.)
Published: October 20, 2025
Endometriosis in Carriers of a Pathogenic Variant in BRCA1 or BRCA2: A Descriptive Analysis of a Large Multicentral BRCA Carrier Cohort.
Journal: Current oncology (Toronto, Ont.)
Published: October 20, 2025
Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: September 26, 2025
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Journal: Nature communications
Published: September 09, 2025
Last Updated: 09/26/2026